Efineptakin alfa Evidence: Trial Results and Peer-Reviewed Publications
Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:
The clinical evidence base for Efineptakin alfa comprises 1 peer-reviewed publications across 1 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including AIDS-related Kaposi sarcoma. Most recent publication: Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma., J Immunother Cancer, 2025.
Top peer-reviewed publications
Curated set of pivotal-trial result papers and recent publications in high-tier journals.
- Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma.Ramaswami R, Kask AS, D'Amico L, et al. · J Immunother Cancer · 2025
Publications by year
2025–2025: 1 publications.
2025
1
Publications by indication
AIDS-related Kaposi sarcoma (1)
- Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma.
Publications by journal
- J Immunother Cancer1 paper
All Efineptakin alfa publications (1)
2025 (1 paper)
- Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma.Ramaswami R, Kask AS, D'Amico L, et al. · J Immunother Cancer · 2025 · Derived
Sources and methodology
- Publications:
ctgov.study_references(PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference typesRESULT,DERIVED, andBACKGROUND. - Per-arm outcome values:
ctgov.outcome_measurementsjoined toctgov.design_outcomeswhereoutcome_type = 'PRIMARY', restricted to phasePHASE3andPHASE2/PHASE3. - Publication metadata (title, journal, year, authors): PubMed E-utilities
efetch.fcgi - Data freshness: Tue, 02 Jun 2026 16:20:39 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).